Heat shock protein 27 (Hsp27) is a 27-kDa molecular chaperone protein that is induced and phospho-activated in response to a variety of cytotoxic stressors, including hormonal, chemo-and radiotherapy. 1 Increased expression of Hsp27 correlates with suppression of apoptosis and improved survival from a variety of cytotoxic insults. In cancer, Hsp27 is frequently overexpressed in numerous malignancies. 2, 3 Elevated expression of Hsp27 in cancer has been associated with poor clinical prognosis and therapeutic resistance. Overexpression of Hsp27 in bladder, colon and prostate cancer cells enhances tumor growth and progression in vivo. [4] [5] [6] Furthermore, selective inhibition of Hsp27 expression with antisense oligonucleotide (ASO)-based therapy has been shown to suppress tumor growth and sensitize cancer cells to hormonal, chemo-and radiotherapy. [3] [4] [5] 7 On the basis of these preclinical proof-of-principle studies, OGX-427, a selective, second-generation ASO inhibitor of Hsp27, has recently advanced into phase I/II clinical trials for treatment of a variety of cancers.
A better understanding of the precise molecular mechanisms by which Hsp27 controls cancer cell survival, death and proliferation may provide novel insights into the mechanism of action of Hsp27 antagonists in cancer therapy, and may facilitate the identification of patients who are most likely to benefit from treatment with Hsp27 inhibitors. Herein, we show that Hsp27 has a critical role in regulating cell proliferation and Fas (death domain containing member of the tumor necrosis factor receptor superfamily)-induced cell death. In the present study, we report that Hsp27 accelerates cell growth of prostate cancer cells by enhancing extracellular signalregulated kinase (ERK) nuclear translocation via regulation of Akt activity and stability that, in turn, leads to increased phosphorylation and stabilization of PEA-15 (15-kDa phospho-enriched protein in astrocytes). Akt-mediated phosphorylation of PEA-15 alters the binding specificity of PEA-15, resulting in its dissociation from ERK alleviating cytoplasmic sequestration of ERK and promoting ERK nuclear translocation, ETS-like transcription factor 1 (Elk-1) activation and cell proliferation; meanwhile PEA-15 phosphorylation enhances its association with Fas-associating protein with a novel death domain (FADD) and suppresses Fas-induced apoptosis. Furthermore, we show that Hsp27 silencing selectively inhibits cell growth of phosphatase and tensin homolog on chromosome 10 (PTEN)-deficient cancer cells.
Results
Hsp27 accelerates LNCaP prostate cancer cell growth by promoting ERK nuclear translocation. The observation that Hsp27 overexpression leads to enhanced tumor growth and progression raises intriguing questions regarding whether Hsp27 might also be able to confer growthpromoting properties that contribute to the process of tumorigenesis, in addition to its cytoprotective functions. To further examine the effects of Hsp27 on cell growth, LNCaP cells were transduced with a lentiviral vector encoding an Hsp27 expression cassette (LNCaP Hsp27 ) or an empty vector (LNCaP mock ) as a control. As shown in Figure 1a , LNCaP Hsp27 cells expressed increased levels of Hsp27 protein that is primarily found in its phosphorylated, activated form. Consistent with previous findings, LNCaP Hsp27 cells exhibited enhanced cell growth as compared with LNCaP mock (Figure 1a ). To investigate whether Hsp27 improves cell growth, in part, by promoting cell cycle progression, cell proliferation of LNCaP mock versus LNCaP Hsp27 cells was analyzed by assessing [ 3 H]-thymidine incorporation as a measure of DNA synthesis and by immunoblotting for panel of typical cell cycle markers. A greater extent of thymidine incorporation was observed in LNCaP Hsp27 than in LNCaP mock cells, indicating that Hsp27 overexpression leads to an increased proportion of cells undergoing DNA synthesis (Figure 1b) . Consistent with the enhanced DNA synthesis, LNCaP Hsp27 cells expressed increased levels of cyclin D1 and CDK2, with a concomitant decrease in cyclin-dependent kinase inhibitor p27 (p27kip1) expression (Figure 1c) . Conversely, small interfering RNA (siRNA)-mediated silencing of Hsp27 inhibits LNCaP cell growth (Figure 1d ). Collectively, these data support the notion that Hsp27 promotes cell proliferation.
Although large, ATP-dependent heat shock proteins, such as Hsp90 and Hsp70, have been shown to interact with many key regulatory components of the cell cycle machinery and the mitogenic signaling cascade, very little is known about the role of Hsp27 in cell proliferation. To assess whether Hsp27 regulates mitogenic signaling via the ERK/MAPK pathway, we assessed the activation status of the ERK/Elk-1 pathway in LNCaP mock versus LNCaP Hsp27 cells. As shown in Figures 1e and f, although LNCaP Hsp27 cells showed a slight/modest increase (B33%) above the already constitutively high levels of phospho-ERK seen in LNCaP mock cells, a marked increase (two-fold) in Elk-1 activity was observed in LNCaP Hsp27 cells versus LNCaP mock cells. The marked signal amplification that is observed suggests that Hsp27 may also function at an additional level downstream of ERK phosphorylation.
Upon phosphorylation, ERK translocates into the nucleus where it mediates its mitogenic effects. Hence, Hsp27 might potentially impinge on the ERK/MAPK pathway at the level of nuclear translocation of ERK. To examine whether Hsp27 regulates ERK translocation, the nucleocytoplasmic distribution of ERK was assessed in LNCaP mock versus LNCaP Hsp27 cells by immunofluorescence microscopy. Indeed, LNCaP Hsp27 cells exhibited increased localization of ERK in the nucleus (Figure 1g ), suggesting that Hsp27 may regulate nuclear translocation of ERK.
Hsp27 regulates ERK translocation via PEA-15. A key regulator of ERK nuclear translocation is a small 15-kDa cytoplasmic phosphoprotein, called PEA-15, that binds to and sequesters ERK in the cytoplasm in a phosphorylationregulated manner. [8] [9] [10] Upon phosphorylation at Ser-116, PEA-15 dissociates from ERK, relieving the cytoplasmic sequestration of ERK and allowing its translocation to the nucleus. To test whether ERK translocation can be regulated by PEA-15 in a phosphorylation-dependent manner, LNCaP cells were transduced with a lentiviral vector expressing a non-phosphorylatable S116G point mutant of PEA-15, or a phosphomimetic S116D point mutant of PEA-15 or an empty vector as a control, and the nucleocytoplasmic distribution of ERK was visualized by immunofluorescence microscopy. Quantitative fluorescence imaging and immunoblotting analyses revealed that LNCaP cells expressing a nonphosphorylatable S116G point mutant of PEA-15 exhibited decreased levels of nuclear ERK compared with LNCaP cells expressing a phosphomimetic mutant of PEA-15 or empty vector-transduced control cells (Figures 2a and b) . Consistent with the levels of nuclear ERK, LNCaP cells expressing a non-phosphorylatable PEA-15 mutant displayed suppressed cell growth as compared with LNCaP cells expressing a phosphomimetic PEA-15 mutant or empty vector control cells (Figure 2c ). Thus, these data support the notion that PEA-15 can regulate ERK translocation and cell proliferation in LNCaP cells in a phosphorylation-regulated manner.
Next, to assess whether ERK translocation in LNCaP cells is controlled in a PEA-15 regulated manner and whether Hsp27 regulates ERK translocation via PEA-15, the nucleocytoplasmic localization of ERK was analyzed in LNCaP cells stably transduced with a lentiviral vector encoding an short hairpin RNA (shRNA)-targeting PEA-15 (LN-221) or an empty lentiviral vector (LNCaP mock ) as control, and treated with either scrambled siRNA (Scr) or Hsp27 siRNA (siHsp27). Importantly, shRNA-mediated silencing of PEA-15 in LN-221 cells (Figure 2d ) resulted in increased nuclear localization of ERK as compared with Scr-treated LNCaP mock cells (Figure 2e ), indicating that PEA-15 is a key regulator of ERK nuclear translocation in LNCaP cells. Furthermore, although siHsp27 treatment of LNCaP mock cells resulted in reduced levels of ERK in the nucleus, the level of nuclear ERK remained high and unchanged upon siHsp27 treatment in PEA-15-knockdown LN-221 cells (Figures 2d and e) . Thus, these data indicate that Hsp27 regulates ERK translocation in a PEA-15-dependent manner.
Hsp27 interacts with and regulates the activity of Akt and PEA-15. Protein kinase B or PKB (also known as Akt) is a cell survival-promoting serine-threonine protein kinase that is activated in a phosphatidylinositol-3' kinase (PI3K)-dependent manner. 11 Hsp27 has previously been shown to bind and activate PKB/Akt in neutrophils. Furthermore, Beguinot and coworkers have shown that PKB/Akt binds, stabilizes and phosphorylates PEA-15 at Ser-116, regulating its activity. 12 Therefore, we explored the possibility that Hsp27 may indirectly regulate PEA-15 by stabilizing and activating Akt.
To examine whether changes in Hsp27 expression levels could modulate total Akt and PEA-15 expression levels as well as Akt activation and PEA-15 phosphorylation, the levels of PEA-15, phospho-PEA-15, Akt, phospho-Akt Ser-473 and phospho-Foxo-1 were analyzed by immunoblotting in LNCaP mock versus LNCaP Hsp27 cells (Figure 3a ). In addition, Figure 3a ). Conversely, Hsp27 silencing led to decreased levels of the indicated proteins and phosphoproteins in a dose-dependent manner (Figure 3b ). These data are consistent with the notion that Hsp27 may regulate PEA-15 by activating Akt, which, in turn, leads to stabilization and phosphorylation PEA-15.
Next, we examined whether Hsp27 and PEA-15 exist in the same protein complex. PEA-15 was immunoprecipitated from LNCaP mock versus LNCaP Hsp27 cells, and from siHsp27-versus Scr-treated LNCaP cells, and the presence of Hsp27 analyzed by immunoblotting. As shown in Figure 3c , increased amounts of Hsp27 coprecipitated with PEA-15 from Hsp27-overexpressing cells, and conversely less Hsp27 was detected in immunoprecipitates from Hsp27-silenced cells (Figure 3c ). These results indicate that Hsp27 interacts, either directly or indirectly, with PEA-15.
To determine whether Hsp27 physically interacts with Akt in LNCaP cells, similar co-immunoprecipitation (co-IP) experiments were performed. Overexpression of Hsp27 increased the amount of Hsp27 that co-immunoprecipitates with Akt, whereas Hsp27 knockdown diminished this interaction (Figure 3d ). To examine whether this interaction is associated with changes in Akt activity, in vitro Akt kinase assays were performed. Similar amounts of Akt were immunoprecipitated from each cell type and subjected to Akt kinase activity assessment using glycogen synthase kinase-3a/b (GSK3a/b) as a substrate. As shown in Figure 3e , Hsp27 silencing decreased Akt activity, whereas increased Akt activity was observed in Hsp27-overexpressing LNCaP Hsp27 cells.
The effect of Hsp27 expression on Akt protein half-life was then evaluated. Cycloheximide (CHX) was added to LNCaP mock , LNCaP Hsp27 and LNCaP cells transfected with Scr or siHsp27 to block de novo protein synthesis, and the levels of Akt protein were monitored by immunoblotting. As shown in Figure 3f , Akt protein levels rapidly decreased after CHX treatment in Hsp27-knockdown cells. In contrast, Hsp27 overexpression prolonged Akt half-life compared with LNCaP cells with empty vector transfected controls. Taken together, these data suggest that Hsp27 directly interacts with and stabilizes Akt, and regulates its activity.
To determine whether Akt is the primary kinase responsible for regulating the phosphorylation of PEA-15 on Ser-116 in LNCaP cells, the effect of Akt inhibition using an Akt-specific siRNA, Akt siRNA (siAkt) or a potent small-molecule Akt inhibitor, GSK690693C, 13 on PEA-15 Ser-116 phosphorylation were assessed by western blot analyses. siAkt treatment downregulated the levels of Akt, phospho-Akt, PEA-15, and phospho-PEA-15, whereas GSK690693C treatment had a dose-dependent decrease of phospho-GSK3b and phospho-PEA-15, accompanied by upregulation of phospho-Akt (Figures 4a and b) . Consistent with previous reports, 12 these data indicate that Akt can regulate PEA-15 phosphorylation and stability, and furthermore, suggest that Akt is the principle kinase that is responsible for phosphorylating PEA-15 at Ser-116 in LNCaP cells.
To test whether Akt activity can regulate ERK translocation, LNCaP cells were treated with or without GSK690693C, and the nucleocytoplasmic localization of ERK was assessed by immunofluorescence microscopy. As shown in Figure 4c , treatment of LNCaP cells with GSK690693C suppressed nuclear translocation of ERK, suggesting that Akt can regulate ERK nuclear translocation. LNCaP cells are intrinsically insensitive to Fas-induced apoptosis, but can be sensitized by treatment with CHX. 15 To determine whether Hsp27 can regulate Fas-induced apoptosis, LNCaP mock and LNCaP Hsp27 cells were treated with 1.0 mg/ml anti-Fas antibody, CH-11, in the presence or absence 2.5 mg/ml CHX. CH-11 treatment had no effect on LNCaP mock and LNCaP Hsp27 cells on its own, but induced apoptosis when it was combined with CHX ( Figure 5a) . However, Hsp27 overexpression in LNCaP Hsp27 cells markedly suppressed CH-11-induced apoptosis. Conversely, Hsp27 knockdown by siHsp27 sensitized LNCaP cells to CH-11-induced apoptosis in the absence of CHX (Figure 5b ). To determine whether the ability of Hsp27 to suppress 16 Furthermore, apoptosis induced by Hsp27 silencing occurs in a PEA-15-independent manner, and PEA-15 silencing does not block Hsp27's cytoprotective activity against apoptosis induced through an intrinsic apoptotic pathway (Figure 5e ). These data collectively suggest that Hsp27 may regulate Fas-induced apoptosis by modifying the interaction of PEA-15 with FADD in LNCaP cells.
Effects of Hsp27 knockdown in PC-3 cells.
To determine whether the effects of Hsp27 on Akt and PEA-15 are not unique to LNCaP cells, we tested whether these Hsp27-mediated changes would hold true on a second PTEN-deficient prostate cancer cell line, PC-3 cells. As with LNCaP cells, siHsp27-mediated silencing resulted in decreased expression levels of total Akt, phospho-Akt (Ser-473), phospho-PEA-15 (Ser-116) and phospho-Foxo-1 (Ser-256) in dose-dependent manner in PC-3 cells (Figure 6a ). In addition, as observed in LNCaP cells, ERK nuclear accumulation clearly decreased after siHsp27 treatment, correlating with decreased phospho-PEA-15 expression level (Figure 6b) . Finally, siHsp27 treatment sensitized Fasresistant PC-3 cells to Fas-induced apoptosis in PC-3 cells as observed previously in LNCaP cells (Figure 6c ).
Hsp27 silencing selectively inhibits PTEN-deficient cancer cells. On the basis of our findings described above that Hsp27 regulates cell proliferation through PEA-15 in an Akt-regulated manner, we hypothesized that the growth inhibitory effects of Hsp27 silencing may be more pronounced in cells that have an activated PI3K/Akt pathway. The PTEN tumor suppressor gene is among the most commonly mutated genes in cancer. 17 PTEN is a lipid phosphatase, which is a key negative regulator of the PI3K/ Akt cell growth and survival pathway. Loss of PTEN confers constitutive activation of the PI3K/Akt pathway, and many cancer cells harboring PTEN mutations become exquisitely dependent on the PI3K/Akt pathway for their growth and survival -a phenomena referred to as 'pathway or oncogene addiction'. 18, 19 To determine whether PTEN expression status is an important predictor for growth inhibition by Hsp27 silencing, the effect of siHsp27 treatment on the growth rates of seven PTEN-positive and five PTEN-deficient cancer cell lines was examined. siHsp27 treatment significantly inhibited cell growth of PTEN-deficient cancer cells, whereas growth rates of PTEN-positive cells were relatively unaffected by Hsp27 silencing (Figure 7a) . Interestingly, PTEN-negative cells also tended to exhibit increased levels of Hsp27 as compared with PTEN-positive cells (Figure 7a ). Figure 7b , siHsp27 treatment led to significant downregulation of Hsp27 expression in PTEN-positive BPH-1 and PTEN-negative MDA468 cells. As expected, PTENdeficient MDA468 cells expressed high levels of phospho-Akt, whereas PTEN-positive BPH-1 cells expressed low basal phospho-Akt levels. Furthermore, siHsp27 treatment resulted in significant downregulation of phospho-Akt and phospho-PEA-15 in MDA468 cells, whereas phospho-Akt and phospho-PEA-15 levels remained low in BPH-1 cells (Figure 7b ). To determine whether the ability of Hsp27 silencing to inhibit cell growth is dependent on PTEN expression, we used the LNCaP PTEN Tet-on cells that express PTEN in a doxycycline (Dox)-inducible manner. Dox treatment of LNCaP PTEN Teton cells resulted in the induction of PTEN expression that was associated with a concomitant downregulation of phospho-Akt and phospho-PEA-15 levels (Figure 7c ). In the absence of Dox, siHsp27 treatment of PTEN-deficient LNCaP PTEN Tet-on cells resulted in significant inhibition of cell growth, whereas upon Dox treatment the growth inhibitory effect induced by Hsp27 silencing was abrogated in PTEN-expressing LNCaP PTEN Tet-on cells (Figure 7d) . In a parallel set of experiments, to test whether the activity of PI3K influences the magnitude of the growth inhibitory effects induced by Hsp27 silencing, the percent growth inhibition induced by siHsp27 treatment of PTEN-deficient PC-3 cells was assessed in cells grown in the presence of varying concentrations of the potent PI3K inhibitor, LY294002. As shown in Figure 7e , LY294002 treatment reduced growth inhibitory effect induced by siHsp27 treatment in a dose-dependent manner. These data demonstrate that growth inhibitory effects induced by Hsp27 silencing may be influenced by the activation status of the PTEN/PI3K/Akt pathway.
As shown in

Discussion
Previous studies have shown that PEA-15 can regulate both the ERK/MAPK pathway and the death receptor-initiated pathway as a result of PEA-15 binding to ERK or FADD, respectively.
14 Akt-mediated phosphorylation of PEA-15 switches the binding specificity of PEA-15 from ERK to FADD, resulting in enhanced proliferation by releasing ERK and allowing its nuclear translocation, while also inhibiting Fas-induced apoptosis via binding and sequestering FADD. Herein, we show that Hsp27 has a critical role in regulating cell proliferation and Fas-induced cell death. The results presented here are consistent with a model (Figure 8 ) wherein the association of Hsp27 with Akt leads to stabilization and activation of Akt, which, in turn, phosphorylates PEA-15 at Ser-116, switching the binding specificity of PEA-15 from ERK to FADD. The dissociation of PEA-15 from ERK alleviates the cytoplasmic sequestration of ERK, allowing its translocation into the nucleus where it mediates its mitogenic effects. Upon phosphorylation of PEA-15 at Ser-116, PEA-15 binds to FADD and thereby inhibits Fas-induced apoptosis.
Here, we show that Hsp27 interacts with Akt in prostate cancer cells. These findings are consistent with previous reports by Konishi et al. 20 and Rane et al. 21 demonstrating that Hsp27 interacts with and promotes activation of Akt in COS-7 kidney cells and neutrophils. Previous findings by Beguinot and coworkers have shown that Akt associates with and stabilizes PEA-15 and that PEA-15 is a downstream substrate of Akt, 12 suggesting that binding of Hsp27 with Akt promotes its stability and activity, and in turn Akt binds, stabilizes and phosphorylates PEA-15 at Ser-116. Consistent with this notion, we find that increased Hsp27 levels correlate with elevated levels of total PEA-15 and phospho-Ser-116-PEA-15.
Hsp27 has been shown to be capable of inhibiting extrinsic cell death triggered by engagement of the Fas death receptor. 22 To date, death-associated protein 6 (Daxx) is the only Hsp27-regulated component of the extrinsic death pathway that has been identified. Hsp27 has been shown to bind to Daxx, preventing the interaction of Daxx with apoptosis signal-regulating kinase 1 (Ask1) and Fas, and inhibiting Daxx-induced apoptosis. 23 Daxx is a death receptor-binding protein that mediates an alternative, FADD-and caspaseindependent death pathway via Ask1 and c-Jun N-terminal kinase. Although Daxx is an important mediator of Fasinduced apoptosis, the ability of Hsp27 to inhibit Daxx alone cannot fully explain the ability of Hsp27 to inhibit the classical Fas-induced FADD-and caspase-dependent death pathway. 22 Here, we show that Hsp27 suppresses Fas-induced apoptosis via promoting FADD-PEA-15 interaction, and that the anti-apoptotic activity of Hsp27 correlates with enhanced phosphorylation of PEA-15 at Ser-116. This is consistent with Despite extensive knowledge of the cytoprotective properties of Hsp27, relatively little is known about the role of Hsp27 in regulating cell proliferation. Here, we show that Hsp27 regulates ERK nuclear translocation in a PEA-15-dependent manner. Ginsberg and coworkers have shown that PEA-15 is a key regulator of ERK nuclear translocation through its ability to directly bind to and sequester ERK in the cytoplasm. 8, 10 Another mechanism by which Hsp27 has been proposed to impact the cell cycle is through its ability to regulate the ubiquitination and degradation of p27kip1. 24 Consistent with this, we have found that p27kip1 levels are downregulated in Hsp27-overexpressing LNCaP cells. The ability of Hsp27 to regulate Akt activity may also contribute to the overall cytoprotective and proliferative functions of Hsp27 11 by regulating the function of pro-apoptotic proteins, such as BAD and caspase-9, cell cycle regulators, such as p27kip1, and mediators that control apoptosis and/or proliferation, such as eIF4E, MDM2, FOXO, GSK3, TSC2 and PRAS40. 11, 25 The concept of oncogenic pathway addiction 19 implies that reversal of one or a few genes can inhibit cancer cell growth and in some cases translate into improved clinical responses. Our findings that Hsp27 silencing preferentially inhibits growth of PTEN-deficient cancer cells suggest that Hsp27 silencing and its downstream effects on Akt may show more pronounced effects on PTEN-deficient cancer cells because of the acquired dependence or addiction of these cells on the PI3K/Akt pathway for their growth and survival. These findings suggest that patients with tumors harboring abnormalities in PTEN function may clinically respond more favorably to OGX-427, thus identifying a population more likely to benefit from Hsp27 inhibition therapy.
Materials and Methods
Cell lines and materials. LNCaP, PC-3, DU145, 293T, Ku7, RT4, UMUC3 and MDA468 cells were purchased from American Type Culture Collection (Rockville, MD, USA). PNT1b provide by Professor N Maitland (York, UK); LAPC4 provided by Dr. Rob Reiter at UCLA, Los Angeles, CA, USA; and BPH-1 cells were a gift from Dr. Simon Hayward, UCSF, San Francisco, CA, USA. LNCaP (used up to passage 50 in the present study), DU145, LAPC4, BPH-1 and PNT1b cells were routinely maintained in RPMI1640 (Life Technologies, Burlington, ON, Canada). RT4 cells were maintained in McCoy's media (Life Technologies). Other cells were maintained in DMEM (Life Technologies). Media were supplemented with 10% fetal bovine serum (FBS), and cultures were grown at 37 1C and 5% CO 2 . GSK690693C, a potent small-molecule Akt inhibitor, was kindly provided by Dr. Rakesh Kumar. CH-11, anti-Fas antibody, was purchased from Upstate (Billerica, MA, USA). CHX, Dox and LY294002 were purchased from Sigma-Aldrich (Oakville, ON, USA). Antibodies against Hsp27, phospho-Hsp27 (Ser-82) (StressGen, Victoria, BC, USA), PEA-15 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-PEA-15 (Ser-116; Biosource, Burlington, ON, Canada), Akt, phospho-Akt (Ser-473), phospho-Foxo-1 (Ser-256; Cell Signaling Technology, Danvers, MA, USA), FADD (Upstate), p27kip1, cyclin D1, CDK2 (Santa Cruz Biotechnology) and vinculin (Sigma-Aldrich) were used according to manufacture's instructions.
Lentiviral transduction of LNCaP cells. Two vectors, pHR
0 -cytomegalovirus (CMV)-Hsp27 and pHR 0 -CMV as an empty vector, were used in the present study as previously described. 4 pHR 0 -CMV-Hsp27 contains the fulllength cDNA for human Hsp27 subcloned into the BamHI and XhoI sites of the pHR 0 -CMV-enhanced green fluorescent protein (GFP) lentiviral vector. Lentiviruses were prepared and transduced into LNCaP cells as described. 4 Expression of GFP and Hsp27 in transduced LNCaP cells was verified by fluorescence microscopy and western blotting, respectively. Lentiviral FLAG-tagged PEA-15 (pLB-U-FPEA-15WT) was derived by PCR and Gateway cloning using the Human PEA-15 cDNA clone (TC108132, OriGene Technologies Inc., Rockville, MD, USA) as template and attB1 and attB2 containing forward 5 0 -GGGGACAAGTTTGTACAAAAAAGCA GGCTTCACCATGGATTATAAAGATGATGACGATAAAGCTGAGTACGGGACCC TCCTG-3 0 and reverse 5 0 -GGGGACCACTTTGTACAAAGCTGGGTCTCAGGCCT TCTTCGGTGG-3 0 primers, respectively. FLAG-tagged PEA-15 S116D (pLB-U-FPEA-15 S116D) was generated by site-directed mutagenesis of Human PEA-15 cDNA clone using the Quick change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's suggested protocol with forward 5 0 -CATTATCCGGCAGCCCGATGAGGAAGAGATCATCAAATTGGC-3 0 and reverse 5 0 -GCCAATTTGATGATCTCTTCCTCATCGGGCTGCCGGATAATG-3 0 primers, respectively, followed by the Invitrogen Gateway cloning technology (Carlsbad, CA, USA) using the PCR primers described above. FLAG-tagged PEA-15 S116G containing seven silent mutations within nucleotides 221-255 were synthesized with flanking 5 0 -EcoR1-attB1 and 3 0 -HindIII-attB2 sites and ligated to pUC57 by Genscript Corporation (Piscataway, NJ, USA). These constructs were generated using a modified lentiviral expression plasmid (FUGW), 26 where the GFP protein was replaced by the Gateway cassette and a blasticidin resistance gene expression module was inserted downstream of the Gateway cassette (pLB-U). All constructs were confirmed by DNA sequence analysis.
siRNA-mediated gene silencing. LNCaP cells were plated at 7 Â 10 5 per 10 cm dish. After 24 h, cells were transfected with siHsp27 or Scr duplexes as previously described. 27 Briefly, the RNA duplex was diluted in Opti-MEM I serumfree medium and Oligofectamin (Invitrogen) and incubated at room temperature for 20 min before addition to cells. The media was changed after 4-6 h. Cells were used 48 h after transfection. The following siRNAs were used: siAkt (Cell Signaling Technology), siHsp27 (5 0 -AAGUCUCAUCGGAUUUUGCAGC-3 0 ; Dharmacon, Lafayette, CO, USA) and Scr (5 0 -CAGCGCUGACAACAGUUUCAU-3 0 ).
Cell proliferation assay. Cells were seeded at 0.5 Â 10 5 cells per well in six-well dishes. At 24 h after culture, cell growth was quantified by direct cell counting at 2-day intervals up to 7 days. Each experiment was repeated three times. Alternatively, cell number was quantified using the Invitrogen CyQuant cell proliferation assay as per the manufacturer's protocols. Flow cytometric bromodeoxyuridine incorporation assay. 5-Bromo-2 0 -deoxyuridine (BrdU) is a synthetic nucleoside analog of thymidine. BrdU is incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication. Cells were incubated with 10 mM BrdU for 2 h, and intracellular staining for BrdU incorporation was performed as per the manufacturer's instructions (BrdU Flow kit; BD Biosciences, San Jose, CA, USA). The percentage of cells undergoing DNA replication was determined by flow cytometry.
Immunofluorescence microscopy. Cells were grown on glass coverslips in standard media for 24 h. Cells were fixed with cold 3% acetone in methanol for 10 min at -20 1C and permeabilized in 0.2% Triton in phosphate-buffered saline (PBS). Slides were incubated in blocking solution, 5% bovine serum albumin in PBS for 1 h and simultaneously treated overnight with primary antibodies, mouse monoclonal Hsp27 and rabbit polyclonal ERK antibodies. Secondary fluorescent antibodies, anti-mouse fluorescein isothiocyanate and anti-rabbit Texas Red Conjugated were added for 1 h at room temperature with three 5-min washes (0.1% Triton in PBS). Cells were counterstained and mounted with coverslips using Vectashield mounting medium containing 4 0 ,6 0 -diaminido-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA). Images were captured using a Zeiss Axioplan II fluorescence microscope (Carl Zeiss Instruments, Oberkochen, Germany) at Â 100 magnification, followed by analysis with imaging software Immunoprecipitation. Cell lysates were incubated with 5 mg anti-Akt, anti-PEA-15 or anti-IgG antibodies. After 12 h of incubation, 50 ml of protein A/G beads (Amersham Pharmacia Biosciences, Piscataway, NJ, USA) was added into the reaction tubes and incubated for 2 h. The beads were washed three times using 1 Â PBS and resolved in 2 Â loading buffer (MBI, Fermentas Inc., Burlington, ON, Canada). The indicated antibody was used, and bands were detected as described above.
In vitro Akt kinase assay. Akt kinase activity was measured using an Akt kinase assay kit (Cell Signaling Technology) according to the manufacture's instructions. Briefly, Akt was immunoprecipitated from cells by incubating cell lysates (500 mg of protein) at 4 1C rotating overnight with protein G-agarose beads bearing anti-Akt antibody. After washing, 1 mg of recombinant GSK3a/b was added to the beads in the presence of magnesium/ATP mixture and incubated for 30 min at 30 1C. SDS sample buffer was then added, samples were boiled for 5 min and electrophoresed on 10% SDS-PAGE. The membranes were probed with antiGSK3a/b (Ser-21/9) and anti-Akt antibodies. Equal amounts of input cell protein were verified by immunoblotting for vinculin.
Protein stability. Cells were cultured in normal growth media for 18-24 h before changing the media to 5% FBS containing RPMI þ 10 mg/ml CHX. Cell lysates were prepared after culturing cells for the indicated lengths of time, and Akt, Hsp27 and GAPDH protein levels were assessed by immunoblotting.
Elk-1 transcription reporter assay. Cells were seeded into 12-well plates at 10 5 cells per well and were transiently cotransfected in Opti-MEM I medium with lipofectin (Invitrogen) with 0.5 mg. GAL-E1b-luciferase reporter gene and varying doses of pCMV-GAL4-Elk-1 kindly provided by Professor Richard A Maurer (OR, USA). Samples were normalized by cotransfection with pCMV-Renilla luciferase. Sixteen hours after transfection, media were replaced with RPMI 1640 plus 10% FBS, and cell lysates were prepared 48 h later. Luciferase activities in cell lysates were quantified using the Dual Luciferase Assay system (Promega, Madison, WI, USA) with the aid of a MicroLumat Plus luminometer (EG&G Berthold, Bad Wildbad, Germany). Reporter assays were expressed in arbitrary light units and performed three times.
Fas-induced apoptosis assay. Cells were treated by either 2.5 mg/ml CHX alone, 1.0 mg/ml anti-Fas antibody (CH-11) alone or in combination in 5% charcoalstripped serum media. Twenty hours later, cells were harvested and the percentage of cells with sub-G0/G1 DNA content was determined by flow cytometry as previously described. 3 In other experiments, cells were transfected with 20 nM Scr or siHsp27 and treated with 1.0 mg/ml CH-11 in low-serum (0.5% FBS) media 48 h after transfection. The proportion of cells containing sub-G0/G1 DNA content after 20 h of CH-11 treatment was determined as a measure of apoptosis as described above. Each experiment was performed three times.
Statistical analysis. All results were expressed as the mean ± S.D. Statistical analysis was performed with a one-way ANOVA, followed by Fisher's protected least significant difference test (StatView 512, Brain Power Inc., Calabasas, CA, USA). *Po0.05 was considered significant.
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